Vyome Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $15.8M
- Price
- $2.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.32%
- Volume
- 4.7K
About
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Quick stats
Shares outstanding7.0M
Computed float1.8M
Float / shares25.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001427570
Websitehttps://www.vyometx.com
AI Summary
AI-generated1/9
minorbullishoperations update
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Vyome Holdings was granted a Chinese patent covering formulation and therapeutic use claims for its proprietary besifloxacin topical gel for inflammatory acne, expanding its IP estate in a market estimated at $600 million.
The company emphasized that its flagship program VT-1953 for malignant fungating wounds remains the clear priority for capital allocation and clinical development efforts.
Management views the patent as a strategic optionality to support future non-dilutive partnering and licensing opportunities in China without shifting focus from its lead asset.